Clinical Trials Logo

Sentinel Lymph Node clinical trials

View clinical trials related to Sentinel Lymph Node.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06169787 Active, not recruiting - Sentinel Lymph Node Clinical Trials

Sentinel Lymph Nodes Biopsy in Cervical Cancer

Start date: October 14, 2023
Phase:
Study type: Observational

This study aims to compare sentinel lymph nodes biopsy versus comprehensive lymphadenectomy in patients with early stage cervical cancer who underwent radical hysterectomy.

NCT ID: NCT05985551 Active, not recruiting - Breast Cancer Clinical Trials

Delayed SLND for Patients With Breast Cancer Undergoing Primary Systemic Treatment

MagNeo
Start date: January 1, 2020
Phase:
Study type: Observational

The goal of this study was to assess the feasibility of SLND by superparamagnetic iron oxide nanoparticles (SPIO) in patients with early breast cancer planned for primary systemic therapy (PST) and whether this is affected by the timeframe of SPIO administration. For this, patients with cN0/1 disease planned for PST received radioisotope as per routine on the day of surgery or the day before, and SPIO was injected in an extended timeframe, at any point from the day of surgery to before the induction of PST. The main points to investigate are: 1. If the SPIO detection rate and concordance to the radiosotope are affected by time of SPIO injection 2. If the nodal yield and the accuracy of the procedure are affected

NCT ID: NCT05359783 Active, not recruiting - Breast Cancer Clinical Trials

Sentinel Node Localization and Staging With Low Dose Superparamagnetic Iron Oxide

MAGSNOW
Start date: November 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Sentinel lymph node (SLN) status is pivotal for treatment decisions in breast cancer patients. The dual technique with Technetium99m (Tc99) and blue dye (BD) is yet the current routine for SLN detection. However, the same reliability has been presented by superparamagnetic iron oxide nanoparticles (SPIO). The aim of this study was to determine if SLN detection using ultra-low dose SPIO is feasible.

NCT ID: NCT05288686 Active, not recruiting - Breast Cancer Clinical Trials

Use of Superparamagnetic Iron Oxide (SPIO) in Sentinel Lymph Node Detection for Breast Cancer

Start date: July 24, 2018
Phase: N/A
Study type: Interventional

Sentinel lymph node biopsy is mandatory during breast cancer operation for disease staging and treatment. The localization of sentinel lymph node is by the injection of radioisotope and blue dye, which is the gold standard. However the use of radioisotope and blue dye are associated with specific drawbacks. Superparamagnetic iron oxide is a magnetic tracer which is FDA-approved for sentinel lymph node localization. The hypothesis of this study is superparamagnetic iron oxide can replace the conventional dual mapping of radioisotope and blue dye in the detection of sentinel lymph nodes for early breast cancers.

NCT ID: NCT04972682 Active, not recruiting - Endometrial Cancer Clinical Trials

[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer

SENTRY
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

While total hysterectomy without lymph node staging is standard for low- and intermediate-risk endometrial cancer, certain histopathologic factors can necessitate additional interventions. Our study assesses the influence of sentinel lymph node (SLN) biopsy on postoperative decision-making.

NCT ID: NCT04303715 Active, not recruiting - Breast Cancer Clinical Trials

No Axillary sUrgical Treatment In Clinically Lymph Node Negative Patients After UltraSonography

Start date: September 15, 2020
Phase: N/A
Study type: Interventional

NAUTILUS study is a prospective, multicenter, RCT. Clinically T1,T2, node negative BCS candidates with no evidence of metastases in AUS are 1:1 randomized into no SLNB group and SLNB group. NAUTILUS study aim to establish the minimally invasive treatment of breast cancer by reexamining the necessity of sentinel lymph node biopsy among patients with invasive breast cancer who have tumors under 5cm, are clinically node-negative, and are having breast conserving surgery performed.